Compare Dicks Sporting Goods Inc (DKS) vs Moderna, Inc. (MRNA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Dicks Sporting Goods Inc vs Moderna, Inc. — how do they compare? Dicks Sporting Goods Inc trades at $136.51 (market cap $13.26B), while Moderna, Inc. trades at $221.7 (market cap $78.65B). The key difference: Moderna, Inc. is far larger — about 5.9× Dicks Sporting Goods Inc's market cap, and Dicks Sporting Goods Inc pays a 3.71% dividend while Moderna, Inc. pays none. Which is the better fit depends on your goals — on Pluang, investors hold Dicks Sporting Goods Inc for 19 Days and Moderna, Inc. for 59 Days on average.
| DKS | MRNA | |
|---|---|---|
Market Cap | $13.26B | $78.65B |
Volume | 2,292,035 | 37,373,437 |
Sector | Consumer Cyclical | Health |
52-Week High | $239.17 | $203.46 |
52-Week Low | $121.15 | $22.36 |
Typical Hold Time | 19 Days | 59 Days |
Enterprise Value | $20.31B | $74.80B |
Dividend Yield | 3.71% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
DICK'S Sporting Goods (DKS) trades at $135.99, up 3.67% today, with a bearish technical signal but strong fundamentals including a P/E of 14.86 and ROE of 18.47%. Recent earnings show mixed results, with a Q2 2026 miss, while revenue grew to $13.44B in 2025. The stock faces headwinds from a securities class action lawsuit, but analysts maintain a buy consensus with a $153.30 price target.
The outlook is cautious due to legal risks and a bearish technical trend, but solid profitability and valuation metrics offer support. Upside potential exists if legal issues resolve and earnings rebound, though investor sentiment is tempered by near-term uncertainties. Risks include litigation outcomes and competitive pressures in retail.
Moderna (MRNA) trades at $214.50, up 9.17% with strong technical momentum. The stock shows bullish moving average signals despite negative profitability metrics, with revenue declining from $18.9B in 2022 to $1.92B in 2025. Recent Nasdaq-100 inclusion creates institutional demand, though Citigroup downgraded to Sell citing valuation concerns after a 500% 2026 rally. The company continues beating EPS expectations despite net losses.
Outlook remains bifurcated between technical strength and fundamental challenges. The cancer vaccine pipeline offers growth potential, but persistent losses and high valuations create headwinds. Near-term momentum may continue from index fund inflows, though profitability concerns warrant caution for long-term investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Dicks Sporting Goods Inc
Dick's Sporting Goods is a leading omni-channel sporting goods retailer in the US It offers an extensive assortment of authentic sports equipment, apparel, footwear, and accessories through its stores and digital platforms.
Read more on DKS →About Moderna, Inc.
Moderna, Inc. operates as a clinical stage biotechnology company. The Company focuses on the discovery and development of messenger RNA (mRNA) therapeutics and vaccines. Moderna develops mRNA medicines for infectious, immuno-oncology, and cardiovascular diseases.
Read more on MRNA →
